Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 0 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
17 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
SOLVAY PHARMACEUTICALS SA from Brussel, company number BE0877542370, closed financial year 2025 with a result of € 904,977 after tax. Compared with financial year 2024, the result moved from € 2.2 million to € 904,977. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 2, 2026.
€ 133,309
▼ 42% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 904,977
▼ 60% vs 2024
Profit after tax over the fiscal year.
€ 1 million paid out
More than the year’s profit went to the shareholders; reserves fell.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 330,410
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 7969 days on average.
€ 156,573
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Profit after taxes | € 832,609 | € 667,062 | € 2,249,269 | € 904,977 | ▼ 60% |
| Equity | € 212,002 | € 179,064 | € 228,333 | € 133,309 | ▼ 42% |
| Total debts | € 2,017,383 | € 1,031,160 | € 2,687,119 | € 1,486,984 | ▼ 45% |
| Cash | - | € 29 | - | - | |
| Retained profit | € 112,002 | € 79,064 | € 128,333 | € 33,309 | ▼ 74% |
| Dividend | € 1,500,000 | € 700,000 | € 2,200,000 | € 1,000,000 | ▼ 55% |
| Balance sheet total | € 31,366,981 | € 29,349,940 | € 32,838,012 | € 28,072,632 | ▼ 15% |
Key figures of SOLVAY PHARMACEUTICALS SA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to SOLVAY PHARMACEUTICALS SA?
What happened at SOLVAY PHARMACEUTICALS SA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Hugues Frisque stepped down as director. NBB
- Emmanuel Vandevelde stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 904,977 (▼ 60% vs 2024). Source: NBB ↗
- Hugues Frisque became a director. NBB
- Emmanuel Vandevelde became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 832,609 profit in 2022 to € 904,977 profit in 2025.
Paid € 332,881 in corporate taxes since 2022.
Best year ever: 2024, with € 2.2 million profit.
Paid out € 5.4 million in dividends to the owners in total.
A new publication or filing at SOLVAY PHARMACEUTICALS SA? We notify you, reason included.
Follow SOLVAY PHARMACEUTICALS SADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Solvay Chlorovinyls SARL (100%).
Directors
According to the 2025 annual accounts
Hugues Frisque
Director
since 2023 · until 2029
since 2023 · until 2029
Shareholders
Solvay Chlorovinyls SARL
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Ransbeekstraat 310
1120 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 17 companies are registered at this address.
All companies at this address →SOLVAY
€ 72.2 million revenue · 2025
Copersol
€ -8,902 gross margin · 2023
SOLVAY CHEMICALS INTERNATIONAL
€ 1.3 billion revenue · 2025
SOLVAY CHIMIE
€ 87.2 million revenue · 2025
Fonds Hannon
+12 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0877.542.370
- VAT number
- BE 0877.542.370
- Registered office
- Ransbeekstraat 310, 1120 Brussel
- Names & denominations
- SOLVAY PHARMACEUTICALS SA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 November 2005
- Peppol
- Active · Active since 19 Feb 2026
- Activities · NACE
Activiteiten van hoofdkantoren
Coördinatiecentra